Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression . Leo Kretzner, PhD, Anna Scuto, PhD, Agnes Juhasz, PhD, Richard Jove, PhD, Yun Yen, MD, Stephen J. Forman, MD and Mark Kirschbaum (accepted for ASH, 2006).
A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week- off Dose Schedule in Acute Myelogenous Leukemia. Mark Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O'Donnell, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, John J. Wright, MD, Bernadette Pulone, RN, Amalia Rincon, MA, Paul Frankel, PhD, Stephen J. Forman, MD and Newman Edward, PhD (accepted for ASH, 2006).
A Radiation-Free Immune and Epigenetics Based Conditioning Regimen for Allogeneic HCT: Combination of Anti-CD3 and Romidepsin. Nainong Li, Chunyan Zhang, Chia-Lei Lin, Bill McCulloch, John Wright, Mark Kirschbaum, Stephen Forman, and Defu Zeng (accepted for ASH, 2006).
GADD45 β in human hepatocellular cancer cells is regulated through histone deacetylation of NF-κB regulation. Chunling Jiang, Bingsen Zhou, Kenneth Fan, Mark Kirschbaum and Yun Yen. (poster presentation, AACR, 2006).
Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome. Eldad J. Dann, Rachel Bar Shalom, Nissim Haim, Ada Tamir, Menachem Ben Shachar, Irit Avivi, Tsila Zuckerman, Mark Kirschbaum, Odelia Goor, Diana Libster, Jacob M. Rowe, Ron Apelbaum Abstract #815 Blood, Volume 106, issue 11, November 16, 2005.
Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide. Richard L. Piekarz, Robin Frye, Maria Turner, John Wright, Steven Allen, Mark H. Kirschbaum, Jasmine Zain, Miles Prince, Susan E. Bates Abstract #231 Blood, Volume 106, issue 11, November 16, 2005.
Peripheral blood stem cells vs bone marrow for matched sibling transplant in AML and ALL remission. Mark Kirschbaum, O’Donnell M, Spielberger R, Bhatia R, Pullarkat V, Stein A, Kogut N, Bolotin E, Chang K, Land J, Sarkodee-Adoo C, Snyder D, Forman SJ. Blood Vol. 104:11 abstract 3321.
The use of reduced intensity allogeneic stem cell transplantation (allo SCT) for recurrence after autologous stem cell transplantation (ASCT) in Hodgkin’s Disease (HD). Amrita Krishnan, Nademanee A, Fung H, Popplewell L, Rodriguez, R, Al-Kadhimi Z, Kirschbaum M, Kogut N, Raubitschek A, Schriber J, Zain J, Smith E, Cheng N, Qian D, Molina A, Forman SJ. Blood Vol. 104:11 abstract 5115.
Impact of allogeneic stem cell t ransplantation (ASCT) on outcome of biphenotypic acute leukemia (BAL). Amrita Krishnan, Chang K, Fung H, O’Donnell M, Bhatia R, Spielberger R, Pullarkat V, Stein A, Kogut N, Kirschbaum M, Bolotin E, Sarkodee Adoo C, Dagis A, Cheng N, Forman SJ. Submitted to ASH December 2004.
Dose intensity and risk of relapse for NHL after allogeneic transplant. Roberto Rodriguez, Nademanee A, Carter N, Smith E, Krishnan A, Popplewell, L, Zain J, Kirschbaum M, Sano Allison, Patane K, Nathwani M, Spielberger R, Sarkodee-Adoo C, Forman SJ. Blood Vol. 104:11 abstract 2311.
Impact of transplant CD34+ cell dose on outcome after allogeneic peripheral blood stem cell transplantation from a matched donor. Nakamura, Ryotaro Smith D, Parker P, Senitzer D, Rodriguez R, Falk P, Fung H, Kirschbaum M, Kogut N, Krishnan A, O’Donnell MR, Popplewell L, Pullarkat V, Sahebi F, Smith E, Snyder D, Spielberger R, Stein A, Zain J, Forman SJ, Nademanee A. Blood 102(11: 488A, 1777 Part 1, Nov 16, 2003.
Tailored BEACOPP regimen for unfavorable Hodgkin lymphoma (HD) based on early response to Ga67 /F18dg scintigraphy and international prognostic score for advanced disease (IPS). Eldad J. Dann, Nisim Haim, Menachem Ben Shachar, Mark Kirschbaum, Odelia Goor, Diana Libster, Ora Israel, Jacob M. Rowe, Rom Epelbaum (ASH: 3081).
Tailored BEACOPP regimen for standard and high risk Hodgkin’s lymphoma: feasibility study using response to ga67 scintigraphy and the intranational prognostic score for advanced Hodgkin’s disease (IPS). Dann EJ ,Israel O, Haim N, Ben-Shahar M, Kirschbaum MH, Rowe JM, Epelbaum R (ASH 2001:4687 Oral Presentation at Israel Society of Hematology May 15, 01; also presented at the recent Lymphoma meetings in Germany and Lugano, being prepared for publication).
Mark H Kirschbaum, MD and Elizabeth Naparstek, MD Mitoxantrone/Cytarabine/Fludarabine (FLAM regimen) combined with donor stem cells as salvage chemo-immunotherapy for relapsed leukemia after allogeneic transplant. (EBMT 2002).
Mark H Kirschbaum, MD and Elizabeth Naparstek, MD High Dose Melphalan/Thiotepa Conditioning Regimen for Resistant Lymphoma. (ASH 2002:5489).
Day 1 Rituximab Day 3 CHOP protocol for bulky small and large cell lymphoma. Kirschbaum MH, Nadav L, Goor O, Eldor A (ASH 2001:4701).
Kirschbaum MH and Yarden Oncogenic Receptor Tyrosine Kinases. Y In: Oncogene-Directed Therapies, Rak, J editor Humana Press (2002).
Kirschbaum MH and Yarden Y The ErbB/HER family of receptor tyrosine kinases: a potential target for chemoprevention of epithelial neoplasms J. of Cellular Biochemistry 2000;77(S34):52-60.
Klapper LN, Kirschbaum MH, Sela M, and Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors In: Advances in Cancer Research, G. Klein and G. Vande Woude, Editors 2000;77:25-79.
Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky Y, Kirschbaum M: Chronic Graft Versus Host Disease treated with UVB phototherapy Bone Marrow Transplantation Dec. 1998 22:12 pp. 1179-1183.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 07/08.